• Something wrong with this record ?

Apoferritin as an ubiquitous nanocarrier with excellent shelf life

S. Dostalova, K. Vasickova, D. Hynek, S. Krizkova, L. Richtera, M. Vaculovicova, T. Eckschlager, M. Stiborova, Z. Heger, V. Adam,

. 2017 ; 12 (-) : 2265-2278. [pub] 20170324

Language English Country New Zealand

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17023149

Due to many adverse effects of conventional chemotherapy, novel methods of targeting drugs to cancer cells are being investigated. Nanosize carriers are a suitable platform for this specific delivery. Herein, we evaluated the long-term stability of the naturally found protein nanocarrier apoferritin (Apo) with encapsulated doxorubicin (Dox). The encapsulation was performed using Apo's ability to disassemble reversibly into its subunits at low pH (2.7) and reassemble in neutral pH (7.2), physically entrapping drug molecules in its cavity (creating ApoDox). In this study, ApoDox was prepared in water and phosphate-buffered saline and stored for 12 weeks in various conditions (-20°C, 4°C, 20°C, and 37°C in dark, and 4°C and 20°C under ambient light). During storage, a very low amount of prematurely released drug molecules were detected (maximum of 7.5% for ApoDox prepared in PBS and 4.4% for ApoDox prepared in water). Fourier-transform infrared spectra revealed no significant differences in any of the samples after storage. Most of the ApoDox prepared in phosphate-buffered saline and ApoDox prepared in water and stored at -20°C formed very large aggregates (up to 487% of original size). Only ApoDox prepared in water and stored at 4°C showed no significant increase in size or shape. Although this storage caused slower internalization to LNCaP prostate cancer cells, ApoDox (2.5 μM of Dox) still retained its ability to inhibit completely the growth of 1.5×10(4) LNCaP cells after 72 hours. ApoDox stored at 20°C and 37°C in water was not able to deliver Dox inside the nucleus, and thus did not inhibit the growth of the LNCaP cells. Overall, our study demonstrates that ApoDox has very good stability over the course of 12 weeks when stored properly (at 4°C), and is thus suitable for use as a nanocarrier in the specific delivery of anticancer drugs to patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023149
003      
CZ-PrNML
005      
20170720124746.0
007      
ta
008      
170720s2017 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/IJN.S130267 $2 doi
035    __
$a (PubMed)28392686
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Dostalova, Simona $u Department of Chemistry and Biochemistry, Mendel University in Brno; Central European Institute of Technology, Brno University of Technology, Brno.
245    10
$a Apoferritin as an ubiquitous nanocarrier with excellent shelf life / $c S. Dostalova, K. Vasickova, D. Hynek, S. Krizkova, L. Richtera, M. Vaculovicova, T. Eckschlager, M. Stiborova, Z. Heger, V. Adam,
520    9_
$a Due to many adverse effects of conventional chemotherapy, novel methods of targeting drugs to cancer cells are being investigated. Nanosize carriers are a suitable platform for this specific delivery. Herein, we evaluated the long-term stability of the naturally found protein nanocarrier apoferritin (Apo) with encapsulated doxorubicin (Dox). The encapsulation was performed using Apo's ability to disassemble reversibly into its subunits at low pH (2.7) and reassemble in neutral pH (7.2), physically entrapping drug molecules in its cavity (creating ApoDox). In this study, ApoDox was prepared in water and phosphate-buffered saline and stored for 12 weeks in various conditions (-20°C, 4°C, 20°C, and 37°C in dark, and 4°C and 20°C under ambient light). During storage, a very low amount of prematurely released drug molecules were detected (maximum of 7.5% for ApoDox prepared in PBS and 4.4% for ApoDox prepared in water). Fourier-transform infrared spectra revealed no significant differences in any of the samples after storage. Most of the ApoDox prepared in phosphate-buffered saline and ApoDox prepared in water and stored at -20°C formed very large aggregates (up to 487% of original size). Only ApoDox prepared in water and stored at 4°C showed no significant increase in size or shape. Although this storage caused slower internalization to LNCaP prostate cancer cells, ApoDox (2.5 μM of Dox) still retained its ability to inhibit completely the growth of 1.5×10(4) LNCaP cells after 72 hours. ApoDox stored at 20°C and 37°C in water was not able to deliver Dox inside the nucleus, and thus did not inhibit the growth of the LNCaP cells. Overall, our study demonstrates that ApoDox has very good stability over the course of 12 weeks when stored properly (at 4°C), and is thus suitable for use as a nanocarrier in the specific delivery of anticancer drugs to patients.
650    _2
$a protinádorové látky $x aplikace a dávkování $x farmakokinetika $x farmakologie $7 D000970
650    _2
$a apoferritiny $x aplikace a dávkování $x chemie $x farmakokinetika $7 D001052
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a doxorubicin $x aplikace a dávkování $x chemie $7 D004317
650    _2
$a nosiče léků $x aplikace a dávkování $x chemie $x farmakokinetika $7 D004337
650    _2
$a lékové transportní systémy $7 D016503
650    _2
$a uvolňování léčiv $7 D065546
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a stabilita léku $7 D004355
650    _2
$a lidé $7 D006801
650    _2
$a koncentrace vodíkových iontů $7 D006863
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádory prostaty $x farmakoterapie $x patologie $7 D011471
650    _2
$a voda $x chemie $7 D014867
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vasickova, Katerina $u Department of Chemistry and Biochemistry, Mendel University in Brno.
700    1_
$a Hynek, David $u Department of Chemistry and Biochemistry, Mendel University in Brno; Central European Institute of Technology, Brno University of Technology, Brno.
700    1_
$a Krizkova, Sona $u Department of Chemistry and Biochemistry, Mendel University in Brno; Central European Institute of Technology, Brno University of Technology, Brno.
700    1_
$a Richtera, Lukas $u Department of Chemistry and Biochemistry, Mendel University in Brno; Central European Institute of Technology, Brno University of Technology, Brno.
700    1_
$a Vaculovicova, Marketa $u Department of Chemistry and Biochemistry, Mendel University in Brno; Central European Institute of Technology, Brno University of Technology, Brno.
700    1_
$a Eckschlager, Tomas $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, University Hospital Motol, Charles University.
700    1_
$a Stiborova, Marie $u Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic.
700    1_
$a Heger, Zbynek $u Department of Chemistry and Biochemistry, Mendel University in Brno; Central European Institute of Technology, Brno University of Technology, Brno.
700    1_
$a Adam, Vojtěch $u Department of Chemistry and Biochemistry, Mendel University in Brno; Central European Institute of Technology, Brno University of Technology, Brno. $7 xx0064599
773    0_
$w MED00176143 $t International journal of nanomedicine $x 1178-2013 $g Roč. 12, č. - (2017), s. 2265-2278
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28392686 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170720125239 $b ABA008
999    __
$a ok $b bmc $g 1238830 $s 984062
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 12 $c - $d 2265-2278 $e 20170324 $i 1178-2013 $m International journal of nanomedicine $n Int J Nanomedicine $x MED00176143
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Archiving options